Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time fucci imaging

Cell Cycle

Volumn 14, Issue 4, 2015, Pages 621-629

  Miwa, Shinji ^a,b,c   Yano, Shuya ^a,b,d   Kimura, Hiroaki ^c   Yamamoto, Mako ^a,b   Toneri, Makoto ^a,b   Matsumoto, Yasunori ^a,b   Uehara, Fuminari ^a,b   Hiroshima, Yukihiko ^a,b   Murakami, Takashi ^a,b   Hayashi, Katsuhiro ^c   Yamamoto, Norio ^c   Bouvet, Michael ^b   Fujiwara, Toshiyoshi ^d   Tsuchiya, Hiroyuki ^c   Hoffman, Robert M ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cancer; Cell cycle; Chemoresistance; Chemosensitivity; Cisplatinum; Doxorubicin; FUCCI; GFP; HeLa; RFP; Time lapse imaging; Tumor heterogeneity

Indexed keywords

CISPLATIN; DOXORUBICIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL FATE; CHEMOSENSITIVITY; DRUG RESISTANCE; FLUORESCENCE; FLUORESCENCE UBIQUITINATION BASED CELL CYCLE INDICATOR IMAGING; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MITOSIS; S PHASE CELL CYCLE CHECKPOINT; CELL LINEAGE; DRUG EFFECTS; FLUORESCENCE IMAGING; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TIME LAPSE IMAGING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINEAGE; CISPLATIN; DOXORUBICIN; HELA CELLS; HUMANS; MITOSIS; NEOPLASMS; OPTICAL IMAGING; PROPORTIONAL HAZARDS MODELS; TIME-LAPSE IMAGING;

EID: 84923613955     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.991604     Document Type: Article

References (38)

1. Levan A, Hauschka TS. Endomitotic reduplication mechanisms in ascites tumors of the mouse. J Natl Cancer Inst 1953; 14:1-21; PMID:13097135
2. Klein G, Klein E. Conversion of solid neoplasms into ascites tumors. Ann NY Acad Sci 1956; 63:640-61; PMID:13314425; http://dx.doi.org/10.1111/j.1749-6632.1956.tb50883.x
3. Makino S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann NY Acad Sci 1956; 63:818-30; PMID:13314436; http://dx.doi.org/ 10.1111/j.1749-6632.1956.tb50894.x
4. Henderson JS, Rous P. The plating of tumor components on the subcutaneous expanses of young mice. J Exp Med 1962; 115:1211-30; PMID:NOT-FOUND; http://dx.doi.org/10.1084/jem.115.6.1211
5. Gray JM, Pierce GB. Relationship between growth rate and differentiation of melanoma in vivo. J Natl Cancer Inst 1964; 32:1201-11; PMID:14191394
6. Prehn RT. Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J Natl Cancer Inst 1970; 45:1039-45; PMID:18605432
7. Mitelman F. The chromosomes of fifty primary Rous rat sarcomas. Hereditas 1971; 69:155-86; PMID:4376138; http://dx.doi.org/10.1111/j.1601-5223.1971.tb02431.x
8. Foulds L. Neoplastic Development, Vol. 1. New York: Academic Press, Inc., 1969.
9. Foulds L. Neoplastic Development, Vol. 2. New York: Academic Press, Inc., 1975.
10. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197:893-5; PMID:887927; http://dx.doi.org/ 10.1126/science.887927
11. Cifone MA, Fidler IJ. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 1981; 78: 6249-52.
12. De Baetseher P, Gorelik E, Eshhar Z, Ron Y, Katzav S, Feldman M, Segal S. Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen Blymphocytes with plasmacytoma cells. J Natl Cancer Inst 1981; 67:1079-87; PMID:6975387
13. Kerbel RS,Dennis JW, Largante AE, Frost P. Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants. Cancer Metastasis Rev 1982; 1:99-140; http://dx.doi.org/10.1007/BF00048223
14. Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44:2259-65; PMID:6372991
15. Heppner GH, Miller BE. Therapeutic implications of tumor heterogeneity. Semin Oncol 1989; 16:91-105; PMID:2652316
16. Goldie JH, Goldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63:1727-33; PMID:526911
17. Schöber C, Gibbs JF, Yin MB, Slocum HK, Rustum YM. Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays. Biochem Pharmacol 1994; 48:997-1002; PMID:8093112; http://dx.doi.org/10.1016/0006-2952(94)90370-0
18. Slocum HK, Parsons JC, Winslow EO, Broderick L, Minderman H, Tóth K, Greco WR, Rustum YM. Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694). Cytometry 2000; 41:252-60; PMID:11084610; http:// dx.doi.org/10.1002/1097-0320(20001201)41:4%3c 252::AID-CYTO3%3e3.0.CO;2-X
19. Yin MB, Voigt W, Panadero A, Vanhoefer U, Frank C, Pajovic S, Azizkhan J, Rustum YM. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Mol Pharmacol 1997; 51:630-6; PMID:9106628
20. Matsui SI, Arredondo MA, Wrzosek C, Rustum YM. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res 1996; 56:4715-23.
21. Bhatia S, Frangioni JV, Hoffman RM, Iafrate AJ, Polyak K. The challenges posed by cancer heterogeneity. Nature Biotech 2012; 30:604-10; http://dx.doi.org/ 10.1038/nbt.2294
22. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132:487-98; PMID:18267078; http://dx.doi. org/10.1016/j.cell.2007.12.033
23. Yano S, Miwa S, Mii S, Hiroshima Y, Uehara F, Yamamoto M, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, et al. Invading cancer cells are predominantly in G0/ G1 resulting in chemoresistance demonstrated by realtime FUCCI imaging. Cell Cycle 2014; 13:953-60; PMID:24552821; http://dx.doi.org/10.4161/cc.27818
24. Miwa S, Yano S, Tome Y, Sugimoto N, Hiroshima Y, Uehara F, Mii S, Kimura H, Hayashi K, Efimova EV, et al. Dynamic color-coded fluorescence imaging of the phase mitosis, and apoptosis demonstrates how caffeine modulates cisplatinum efficacy. J Cell Biochem 2013; 114:2454-60; PMID:23696238; http://dx.doi.org/ 10.1002/jcb.24593
25. Yano S, Zhang Y, Zhao M, Hiroshima Y, Miwa S, Uehara F, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, et al. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle 2014, 13:3958-63.
26. Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007; 6:70-4; PMID:17245109; http://dx.doi.org/10.4161/cc.6.1. 3682
27. Blagosklonny MV. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors. Cell Cycle 2011; 10:2295-8; PMID:21715978; http://dx.doi.org/ 10.4161/cc.10.14.16819
28. Leontieva OV, Gudkov AV, Blagosklonny MV. Weak p53 permits senescence during cell cycle arrest. Cell Cycle 2010; 9:4323-7; PMID:21051933; http://dx. doi.org/10.4161/cc.9.21.13584
29. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, Bokemeyer C, Mayer F. Cell-cycle progression and response of germ cell tumors to cisplatinum in vitro. Int J Oncol 2006; 29:471-9; PMID:16820891
30. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005; 4:269-78; PMID:15655345
31. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89:1147-51; PMID:14520435; http://dx.doi.org/10.1038/sj.bjc.6601256
32. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8:1104-7; PMID:14678733; http://dx.doi.org/10.1016/S1359-6446(03)02806-X
33. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307-12; PMID:18487952; http://dx.doi.org/ 10.4161/cc.7.10.6250
34. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell Cycle 2005; 4:1518-21; PMID:16258270; http:// dx.doi.org/10.4161/cc.4.11.2208
35. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrugresistant cells but protects normal cells. Leukemia 2001; 15:936-41; PMID:11417480; http://dx.doi.org/ 10.1038/sj.leu.2402127
36. Blagosklonny MV. Target for cancer therapy: proliferating cells or stem cells. Leukemia 2006; 20:385-91; PMID:16357832; http://dx.doi.org/10.1038/sj.leu. 2404075
37. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6:1684-90; PMID:18344680; http://dx.doi.org/ 10.4161/cbt.6.11.5167
38. Uchugonova A, Zhao M, Weinigel M, Zhang Y, Bouvet M, Hoffman RM, Koenig K. Multiphoton tomography visualizes collagen fibers in the tumor microenvironment that maintain cancer-cell anchorage and shape. J Cell Biochem 2013; 114:99-102.